Core Viewpoint - Ginkgo Bioworks Holdings, Inc. (DNA) experienced a significant stock price increase of 14.5% to $16.36, driven by positive investor sentiment regarding its proprietary cell programming platforms and strong revenue growth expectations [1][2]. Company Summary - Ginkgo Bioworks utilizes its Foundry and Codebase platforms to offer R&D services under collaboration and license agreements, along with biomonitoring and bioinformatic support services to public health authorities [2]. - The company is projected to report a quarterly loss of $1.45 per share, reflecting a year-over-year increase of 59.7%, while revenues are expected to reach $45.08 million, marking a 29.7% increase from the previous year [3]. - The consensus EPS estimate for Ginkgo Bioworks has remained stable over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4]. Industry Context - Ginkgo Bioworks is part of the Zacks Medical - Biomedical and Genetics industry, which includes other companies like Krystal Biotech, Inc. (KRYS), that has shown a modest stock performance with a 0.7% increase [4]. - Krystal Biotech's EPS estimate has increased by 10.6% over the past month, indicating a significant year-over-year change of 330%, but it currently holds a Zacks Rank of 4 (Sell) [5].

Core Insights - Ginkgo Bioworks is launching the 2025 Ferment Series, an evolution of its annual conference aimed at advancing its mission of making biology easier to engineer [1][2] - The series will focus on specific areas within Ginkgo's cell engineering and biosecurity offerings, showcasing transformative solutions across various markets [2][3] Event Details - The Ferment Series will take place at Ginkgo's event venue in Boston's Seaport District, with a series of focused events throughout 2025 [1] - Each event will feature Ginkgo experts, partners, and industry leaders discussing applications of engineered biology [2] Technology and Innovations - Attendees will have the opportunity to see Ginkgo's technologies and innovations, including high-throughput AI-driven data generation services and automation systems [3] - New products and services will be highlighted, such as Ginkgo Datapoints and Ginkgo Biosecurity's monitoring and threat intelligence solutions [3] CEO Statement - Jason Kelly, CEO of Ginkgo Bioworks, emphasized the company's strengthened mission and the importance of showcasing their evolving platform and new capabilities at the 2025 Ferment events [4] 2025 Ferment Series Calendar - The series will include events focused on: - Summer: Datapoints x AI, focusing on data generation services and AI models for biotech R&D [5] - September: Ginkgo Biopharma Solutions, aimed at accelerating drug discovery and development [5] - October: Biosecurity, discussing strategies for biological risk management [5] - November: Automation, featuring demonstrations of Ginkgo's automation systems [6] Industry Engagement - Ginkgo will also participate in other industry conferences, such as World AgriTech and ABIM, to connect with partners and showcase its R&D capabilities [7][8]

Ginkgo Bioworks Holdings, Inc. (DNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The ...

Customizable, anaerobic-enabled system aims to accelerate discovery and development of sustainable biofuels at the University of Wisconsin–Madison's GLBRCBOSTON, Jan. 23, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and deploy a flexible, anaerobic-enabled laboratory automation system for the Great Lakes Bioenergy Research Center (GLBRC), a U.S. Department of Energy-funded Bio ...

Core View - Ginkgo Bioworks collaborates with Universal Cells, an Astellas company, to optimize next-generation iPSC-derived cancer cell therapies, leveraging Ginkgo's high-throughput biological approaches to address challenges in solid tumor therapy development [1] - The collaboration aims to enhance the potency and persistence of iPSC-derived immune cell therapeutics by combining Universal Cells' proprietary technologies with Ginkgo's expertise in CAR library design, screening, and immune cell engineering [2] Collaboration Details - The partnership focuses on improving the scalability and manufacturability of 'off-the-shelf' iPSC-derived cell therapies, which have the potential to transform cancer care [2] - Ginkgo's platform capabilities include CAR discovery and optimization, cell survival enhancement strategies, and gene editing tools for immune cell engineering, enabling rapid exploration and refinement of therapeutic designs [3] Ginkgo's Platform Strengths - Ginkgo employs computational tools, deep expertise in library assembly, and rigorous statistical analysis to accelerate the discovery and engineering of optimal therapeutic designs [3] - The company's high-throughput pooled and arrayed screening methods allow simultaneous testing of numerous CAR designs, aiming to improve immune cell persistence and functionality [3] Strategic Impact - The collaboration represents a significant milestone for Ginkgo as it expands its cell therapy portfolio and brings its immune cell engineering capabilities to a global pharmaceutical leader [4] - The partnership aims to optimize iPSC-derived allogeneic cell therapies, potentially improving patient outcomes and reshaping the treatment of solid tumors [4] Industry Context - Ginkgo Bioworks is a leading horizontal platform for cell programming, offering end-to-end services across diverse markets, including pharmaceuticals, food, agriculture, and industrial chemicals [5] - The company is also building next-generation biosecurity infrastructure and technologies to address global biological threats [5]

Company Presentation - Ginkgo Bioworks CEO Jason Kelly is scheduled to present at the 43rd Annual J P Morgan Healthcare Conference on January 16 2025 at 10 30 a m PT (1 30 p m ET) [1] - Further details webcast link and a replay of the presentation will be posted on the company's investor relations website [1] Company Overview - Ginkgo Bioworks is the leading horizontal platform for cell programming providing flexible end-to-end services across diverse markets including food and agriculture pharmaceuticals and industrial and specialty chemicals [2] - Ginkgo Biosecurity is building next-generation infrastructure and technologies to help global leaders predict detect and respond to biological threats [2] Contact Information - Investor contact email is provided for inquiries [3] - Media contact email is provided for inquiries [3]

Ginkgo Bioworks Holdings, Inc. (DNA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. ...

Ginkgo Bioworks to apply its mammalian cell engineering expertise to develop new cell-based systems for treating and monitoring endocrine disordersBOSTON, Dec. 17, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a subcontract of up to $9.4 million awarded in partnership with Carnegie Mellon University to develop bioelectronic cell-based devices aimed at diagnosing and treating hormone disorders. This initiative is ...

Ginkgo Bioworks (NYSE: DNA ) reported solid results in the third quarter, although the company's performance was weaker than the financials suggest, as Ginkgo recognized 45 million USD of non-cash revenue that has no value. Ginkgo's transition away from downstream value Richard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be ach ...

I am a market enthusiast and part-time trader. I started writing for Seeking Alpha in 2011, and it has been a tremendous opportunity and learning experience. I have been interested in the markets since elementary school, and hope to pursue a career in the investment management industry. I have been active in the markets for several years, and am primarily focused on long/short equities. I hold a Bachelor of Science Degree from Lehigh University, where I double majored in Finance and Accounting, with a minor ...